Liquidia Technologies, Inc. (NASDAQ:LQDA - Get Free Report) CEO Roger Jeffs sold 20,252 shares of the firm's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $14.28, for a total value of $289,198.56. Following the completion of the sale, the chief executive officer directly owned 1,038,560 shares in the company, valued at $14,830,636.80. This trade represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Liquidia Technologies Trading Down 1.5%
NASDAQ LQDA traded down $0.22 on Friday, hitting $14.38. The company's stock had a trading volume of 842,021 shares, compared to its average volume of 1,301,514. Liquidia Technologies, Inc. has a 52-week low of $8.26 and a 52-week high of $19.41. The company has a current ratio of 2.93, a quick ratio of 2.91 and a debt-to-equity ratio of 2.08. The company's 50-day simple moving average is $14.88 and its 200 day simple moving average is $14.48. The firm has a market cap of $1.23 billion, a P/E ratio of -9.12 and a beta of -0.01.
Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The business had revenue of $3.12 million during the quarter, compared to analysts' expectations of $3.23 million. Liquidia Technologies had a negative return on equity of 177.91% and a negative net margin of 903.80%. Research analysts predict that Liquidia Technologies, Inc. will post -1.51 EPS for the current fiscal year.
Analyst Ratings Changes
Several analysts recently weighed in on the company. HC Wainwright raised their price objective on Liquidia Technologies from $29.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday, May 28th. Wells Fargo & Company lifted their price target on Liquidia Technologies from $23.00 to $25.00 and gave the company an "overweight" rating in a research note on Thursday, June 12th. Needham & Company LLC reissued a "buy" rating on shares of Liquidia Technologies in a research note on Monday, June 2nd. Bank of America cut their price target on Liquidia Technologies from $25.00 to $23.00 and set a "buy" rating on the stock in a research note on Wednesday, June 11th. Finally, Scotiabank lifted their price target on Liquidia Technologies from $36.00 to $37.00 and gave the company a "sector outperform" rating in a research note on Wednesday, May 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $26.89.
View Our Latest Report on Liquidia Technologies
Institutional Investors Weigh In On Liquidia Technologies
Hedge funds and other institutional investors have recently modified their holdings of the business. Hurley Capital LLC purchased a new position in Liquidia Technologies during the 1st quarter worth $32,000. GAMMA Investing LLC boosted its position in Liquidia Technologies by 65.6% during the 1st quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock valued at $44,000 after acquiring an additional 1,173 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new stake in Liquidia Technologies during the 4th quarter valued at $59,000. Quarry LP bought a new stake in Liquidia Technologies during the 1st quarter valued at $79,000. Finally, Summit Investment Advisors Inc. boosted its position in shares of Liquidia Technologies by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after purchasing an additional 1,719 shares in the last quarter. 64.54% of the stock is currently owned by hedge funds and other institutional investors.
About Liquidia Technologies
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Recommended Stories
Before you consider Liquidia Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia Technologies wasn't on the list.
While Liquidia Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
